Denali Therapeutics (DNLI) Assets Average (2018 - 2026)

Denali Therapeutics (DNLI) has 9 years of Assets Average data on file, last reported at $1.2 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $1.2 billion, down 8.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 8.87% YoY), and the FY2025 annual result was $1.3 billion, changed 0.36% from the prior year.
• Assets Average improved to $1.2 billion in Q1 2026 per DNLI's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Assets Average peaked at $1.5 billion in Q2 2024 and troughed at $1.1 billion in Q4 2025.
• A 5-year average of $1.3 billion and a median of $1.3 billion in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average advanced 18.3% in 2024, then slipped 24.85% in 2025.
• A 5-year view of Assets Average shows it stood at $1.3 billion in 2022, then retreated by 11.06% to $1.2 billion in 2023, then increased by 18.3% to $1.4 billion in 2024, then dropped by 22.2% to $1.1 billion in 2025, then grew by 9.56% to $1.2 billion in 2026.
• Business Quant data shows DNLI's Assets Average at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.